Targeted Therapy for Hepatocellular Carcinoma

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Hepatocellular cancer (HCC) is a leading cause of cancer death worldwide, and most patients who are diagnosed with HCC are ineligible for curative local therapy. The targeted agent sorafenib provides modest survival benefits in the setting of advanced disease. Novel systemic treatment options for HCC are sorely needed. In this review, we identify and categorize the drugs and targets that are in various phases of testing for use against HCC. We also focus on the potential for combining these agents with radiotherapy. This would help identify directions for future study that are likely to yield positive findings and improve outcomes for patients with HCC.

Original languageEnglish (US)
Pages (from-to)338-343
Number of pages6
JournalSeminars in Radiation Oncology
Issue number4
StatePublished - Oct 1 2016

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Targeted Therapy for Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this